Clinical Trial Update: Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating surufatinib with durvalumab and EP/EC as first-line treatment for extensive-stage small-cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• EP/EC (EP/EC)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Beijing Chest Hospital | Conditions: Extensive-stage Small-cell Lung Cancer | Phase 2 | Status: UNKNOWN